Navigation Links
Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
Date:6/25/2010

US Food and Drug Administration's Office of Orphan Products Development. Soligenix and UT Southwestern have collectively received approximately $25 million in grant funding from the NIH for development of RiVax™ and related vaccine technologies.

About Ricin Toxin

Ricin toxin is a plant toxin thought to be a bioterror threat because of its stability and high potency as well as the large worldwide reservoir created as a by-product of castor oil production. Exposure to ricin results in local tissue necrosis, and general organ failure leading to death within several days of exposure. The potential use of ricin toxin as a biological weapon has been highlighted in an FBI terrorism report, which states that "Ricin and the bacterial agent anthrax are emerging as the most prevalent agents involved in WMD investigations" (http://www.fbi.gov/publications/terror/terrorism2002_2005.pdf).

There are currently no effective means to prevent the effects of ricin intoxication. The successful development of an effective vaccine against ricin toxin may act as a deterrent against the actual use of ricin as a biological weapon and could be used in rapid deployment scenarios in the event of a biological attack. RiVax™ would potentially be added to the Strategic National Stockpile and dispensed in the event of a terrorist attack.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
(Date:9/1/2015)... Sept. 1, 2015  Dynatronics Corporation (NASDAQ: ... at the First Annual Ladenburg Thalmann Healthcare Conference ... Kelvyn H. Cullimore, Jr. , Chairman and ... investment representatives on Tuesday, September 29 at 10:30 ... Conference will showcase leading-edge companies in the healthcare ...
(Date:9/1/2015)... -- Dr. Cindy Orser , the Chief Science Officer ... of DigiPath, Inc. (OTCQB: DIGP), was recently interviewed ... consistency in today,s medical cannabis testing industry. In her ... she explained that the state-to-state variations in cannabis laws ... makes standardization impossible. Dr. Orser is ...
Breaking Medicine Technology:Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3
... China , April 29 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. (NYSE ... pharmaceuticals company in China , today announced,that it has retained CCG ... , , ... to working with CCG to establish more effective and,transparent communications channels with ...
... , April 29 Royal Philips Electronics ( ... provider of integration solutions in healthcare, to deploy the Orion Health Rhapsody® ... , , ... , , ...
Cached Medicine Technology:China Pharma Holdings, Inc. Retains CCG Investor Relations 2China Pharma Holdings, Inc. Retains CCG Investor Relations 3China Pharma Holdings, Inc. Retains CCG Investor Relations 4China Pharma Holdings, Inc. Retains CCG Investor Relations 5Philips and Orion Health Partner to Deliver on Enterprise Interoperability 2Philips and Orion Health Partner to Deliver on Enterprise Interoperability 3Philips and Orion Health Partner to Deliver on Enterprise Interoperability 4
(Date:9/1/2015)... ... September 01, 2015 , ... Stress comes in ... from everyday life changes can lead to very serious, life-altering events. Fortunately nature ... with stress. Herbal supplement manufacturer MediHerb has coupled therapeutic doses of ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the ... societal issues and needs. Money for Good 2015, released today by Camber Collective, goes ... an annual potential to mobilize up to $22B in new philanthropic giving and shift ...
(Date:9/1/2015)... London, UK (PRWEB) , ... ... ... are constantly seeking better therapeutic options to efficiently cure and prevent different ... classes. Different cancers have different pathophysiological properties due to which distinctive approach ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Splashtop Business for Remote Support , a solution optimized for MSPs and ... with the escalating renewal prices and inadequate customer services of existing remote support ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in Houston, ... Touch® , an innovative vaginal health laser procedure that prevents and resolves dryness ... for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful intercourse ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3
... nasal steroids don,t lessen symptoms , , TUESDAY, Dec. 4 ... better than a placebo in combating sinus infections, a ... as effective as have been previously believed, particularly for ... author Dr. Ian Williamson, a senior lecturer in primary ...
... Tampa, Fla. (December 4, 2007) A study carried ... Medicine and published in the current issue of CELL ... bone marrow cells (BMCs) containing adult stem cells are ... bio-engineered materials, they successfully help regenerate damaged nerves. The ...
... and OMX Nordic Exchange: EPCT) announced today the pricing ... common stock at $1.50,per share and five-year warrants to ... at an exercise price of $1.50 per share.,EpiCept will ... Rodman & Renshaw, LLC, a subsidiary of Rodman & ...
... Biopure Corporation,(Nasdaq: BPUR ) announces the ... Society for Clinical Pharmacology and Therapeutics annual,meeting to ... the largest scientific,and professional organization serving the discipline ... for adverse event outcomes and other,key findings in ...
... mice use energy less efficiently, researchers report in the ... Press, that they have delayed the animals deaths and ... and one form of cancer. Those health benefits, driven ... any direct influence on the aging process itself, according ...
... HOUSTON, Dec. 4, 2007 -- Robotics engineers at Rice ... develop a PC-based system for physical rehabilitation. , "It ... to regain the use of their limbs," said system ... Interfaces Laboratory (MAHI). "We hope to refine our system ...
Cached Medicine News:Health News:Sinusitis Treatments Found Ineffective 2Health News:Sinusitis Treatments Found Ineffective 3Health News:Bone marrow cell transplants help nerve regeneration 2Health News:EpiCept Corporation Announces Pricing of Public Offering 2Health News:EpiCept Corporation Announces Pricing of Public Offering 3Health News:Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics 2Health News:Fighting diseases of aging by wasting energy 2Health News:Fighting diseases of aging by wasting energy 3Health News:Robotics lab helps stroke patients with recovery 2
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
... The Carriazo-Pendular microkeratome is based ... of the cornea during the cut., ... applanated evenly from the beginning of ... ensures that the intraocular pressure does ...
Medicine Products: